Glenmark Pharmaceuticals advances on launching ‘Digihaler’

26 May 2016 Evaluate

Glenmark Pharmaceuticals is currently trading at Rs. 861.00, up by 1.25 points or 0.15% from its previous closing of Rs. 859.75 on the BSE.

The scrip opened at Rs. 862.30 and has touched a high and low of Rs. 862.55 and Rs. 859.65 respectively. So far 2,388 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1261.95 on 21-Aug-2015 and a 52 week low of Rs. 671.50 on 12-Feb-2016.

Last one week high and low of the scrip stood at Rs. 880.00 and Rs. 851.00 respectively. The current market cap of the company is Rs. 24,274.75 crore.

The promoters holding in the company stood at 46.48% while Institutions and Non-Institutions held 41.92% and 11.60% respectively.

Glenmark Pharmaceuticals has launched Digihaler, a Digital Dose Inhaler (DDI). This next-gen inhaler provides accurate digital dose counter along with low dose warning indicator to enable asthma and chronic obstructive pulmonary disease (COPD) patients to track adherence to their therapy. The development comes on the back of patients’ compliance being a challenge globally when it comes to chronic disease treatment.

Glenmark Pharmaceuticals is a pharmaceutical company headquartered in Mumbai, India. It manufactures and markets generic formulation products and active pharmaceutical ingredients, both in the domestic and international markets.


Glenmark Pharma Share Price

2011.60 -24.30 (-1.19%)
01-Jan-2026 13:49 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.95
Dr. Reddys Lab 1249.95
Cipla 1499.90
Zydus Lifesciences 912.90
Lupin 2099.90
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×